跳转至内容
Merck

SML2218

Sigma-Aldrich

SNS-032

≥98% (HPLC)

别名:

BMS-387032, N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H24N4O2S2
分子量:
380.53
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL

儲存溫度

−20°C

SMILES 字串

O=C(NC1=NC=C(SCC2=NC=C(C(C)(C)C)O2)S1)C3CCNCC3

InChI

1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22)

InChI 密鑰

OUSFTKFNBAZUKL-UHFFFAOYSA-N

生化/生理作用

SNS-032 (BMS-387032) is a selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9 that regulate the cell cycle and transcription. It has IC50 values of 38 nM for Cdk2, 62 nM for Cdk7, and 4 nM for Cdk9. SNS-032 was in clinical trials for a variety of cancers including chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rong Chen et al.
Blood, 113(19), 4637-4645 (2009-02-24)
Inhibitors of cyclin-dependent kinases (Cdks) have been reported to have activities in chronic lymphocytic leukemia cells by inhibiting Cdk7 and Cdk9, which control transcription. Here we studied the novel Cdk inhibitor SNS-032, which exhibits potent and selective inhibitory activity against
Calla M Olson et al.
Nature chemical biology, 14(2), 163-170 (2017-12-19)
Cyclin-dependent kinase 9 (CDK9), an important regulator of transcriptional elongation, is a promising target for cancer therapy, particularly for cancers driven by transcriptional dysregulation. We characterized NVP-2, a selective ATP-competitive CDK9 inhibitor, and THAL-SNS-032, a selective CDK9 degrader consisting of
Daniela Cihalova et al.
Cancer chemotherapy and pharmacology, 76(1), 105-116 (2015-05-20)
ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro: P-glycoprotein (ABCB1), breast cancer resistance

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门